Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes

Ceribell, Inc. announced the publication of a study in *Critical Care Medicine* demonstrating that its Clarity AI algorithm’s measure of seizure burden correlates with patient outcomes at discharge. The research, conducted across Yale School of Medicine, Massachusetts General Hospital, and the University of New Mexico, analyzed data from 359 adult patients with both Ceribell’s point-of-care EEG and conventional EEG monitoring. The study revealed that higher seizure burden detected by Clarity was associated with a 3.4-fold increase in severe disability or death, compared to patients with no seizure activity. Each additional hour of seizure activity raised the risk nearly twofold, confirming a clear dose-response relationship between seizure burden and poor outcomes. This is the first validated bedside tool linking AI-estimated seizure burden to functional outcomes, even after adjusting for clinical factors. The findings build on Ceribell’s earlier SAFER-EEG study published in *Neurology* (July 2024), reinforcing the utility of real-time AI-driven monitoring in emergency and critical care settings. Jane Chao, Ph.D., Ceribell’s co-founder and CEO, emphasized the shift from delayed assessments to continuous brain monitoring, enabling faster clinical decision-making for critically ill patients. The study underscores the potential of AI in acute neurological care, offering physicians actionable insights to prioritize interventions and improve survival rates. Ceribell’s Clarity system is positioned as a critical tool for addressing unmet needs in rapid neurodiagnostics, particularly in ICUs and emergency departments.